June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Monocyte Biomarkers of Early-Intermediate Age-Related Macular Degeneration
Author Affiliations & Notes
  • Aden Swayze
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Leonie Kurzlechner
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Malina Sexton
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Alan D Proia
    Pathology, Duke University Medical Center, Durham, North Carolina, United States
  • Simone Degan
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Eleonora M Lad
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Aden Swayze None; Leonie Kurzlechner None; Malina Sexton None; Alan Proia Roche, Code F (Financial Support); Simone Degan None; Eleonora Lad Roche, Code F (Financial Support)
  • Footnotes
    Support  VA Merit Award I01 CX002116-01 (ELad); Unrestricted Research to Prevent Blindness Grant (Duke Eye Center); NIH Core Grant P30EY005722 (Duke Eye Center)
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 362 – F0193. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aden Swayze, Leonie Kurzlechner, Malina Sexton, Alan D Proia, Simone Degan, Eleonora M Lad; Monocyte Biomarkers of Early-Intermediate Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):362 – F0193.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To employ a flow cytometry gating strategy to investigate blood-based monocyte biomarkers of early-intermediate age-related macular degeneration (AMD) and determine the relationship between monocytes and disease stage on flow cytometry and immunohistochemistry (IHC).

Methods : We recruited 30 study participants: 9 with early AMD (eAMD; category 2 AREDS), 11 with intermediate AMD (iAMD; category 3 AREDS), and 10 normal controls. Samples were matched by age (+/-5 years) and gender. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples and then stained with CD45, CD14, CD16, CD163, CD11a, and CD11b antibodies. We used a flow cytometry gating strategy to identify PBMC subsets (classical, intermediate, and non-classical). In parallel, we performed co-localization IHC studies of CD163+ and CD68+ macrophages in the macula of postmortem eyes with iAMD (stage Sarks 4; N=7) and normal control eyes (stage Sarks 1; N=7).

Results : On flow cytometry, the proportion of CD68+ cells was lowest in the PBMCs from iAMD participants (52.3% vs eAMD 77.7% and normal 60.9%), and there was a significant difference between the early and iAMD groups (p<0.05). iAMD samples demonstrated the highest percentage of CD163+ cells (8.7% vs eAMD 2.3%, normal 5.3%; p= 0.54) and nonclassical monocytes (5.9% vs eAMD 4.5%, normal 4.4%; p= 0.62), although the results did not reach significance. Within CD68+ and CD163+ cells, there were no significant differences between groups with respect to PBMC subsets. However, we found a moderate correlation between CD163-high cells and the intermediate PBMC subset (r2= 0.35).

The quantitative IHC analysis showed a decreased expression of CD163 in the macrophages in the choroid and inner retina of iAMD Sarks 4 postmortem eyes and an increased CD163 expression in the outer retina as compared to normal Sarks 1 eyes (all p<0.05). No significant differences in CD68 expression were observed between the iAMD Sarks 4 and normal Sarks 1 groups.

Conclusions : Our data suggest that CD163+ monocytes/macrophages are associated with disease stage in early-intermediate AMD, implicating these cells in the pathobiology and progression of AMD. CD163 may represent a useful clinical blood-based biomarker of disease progression on flow cytometry analysis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×